Management ChangeAug 4, 2026, 08:07 AM
Rani Therapeutics Appoints Michelle Gilson to Board, Audit Chair
AI Summary
Rani Therapeutics Holdings, Inc. announced the appointment of Michelle Gilson to its Board of Directors, effective August 1, 2026. Ms. Gilson will also assume the role of chair of the Audit Committee. She brings extensive financial and biotechnology experience, having most recently served as Chief Financial Officer of Arcellx, Inc. until its acquisition by Gilead Sciences, Inc. in April 2026, and previously as a Senior Biotechnology Equity Research Analyst.
Key Highlights
- Michelle Gilson appointed to Rani Therapeutics' Board of Directors, effective August 1, 2026.
- Ms. Gilson will also serve as chair of the Audit Committee.
- She previously served as CFO of Arcellx, Inc. from May 2022 until its acquisition in April 2026.
- Her prior experience includes roles as a Senior Biotechnology Equity Research Analyst at Canaccord Genuity Group Inc. and various investment banking firms.
- Ms. Gilson will be compensated as a non-employee director per the Company’s policy.
Price Impact
More from RANI